Login to Your Account



Stressgen's HspE7 Positive In Cervical Dysplasia Study

By Karen Pihl-Carey


Thursday, November 18, 2004
Demonstrating a 40 percent response rate in high-grade cervical dysplasia patients, Stressgen Biotechnologies Corp.'s lead candidate, HspE7, appears to be heading toward another Phase III trial. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription